Unlocking the Power of Real-World Clinical Data & Single-Cell Multi-omics to Accelerate Breakthroughs in Precision Medicine

What the Company Does

RefinedScience team of experts in clinical medicine, molecular and cellular biology, data science and pharma turn insights into advancements in care. Through the power of big data, single cell omics and AI RefinedScience aim to identify effective therapies, diagnostics and other key breakthroughs and deliver them to the patients who need them the most.

Current Landscape

RefinedScience’s transformative insights identify and validate novel drug targets, design smarter clinical trials, and forge paths for stalled clinical-stage drug candidates. The company’s approach can significantly increase the probability of success while shaving off millions of dollars and years in the process.

PROBLEM: Drug development is SLOW, COSTLY, and RISKY: 

• $161B spent on R&D by largest pharma companies in 2023.
• +8.5% increase in R&D costs per year over last decade
• $200B annual revenue at risk through 2030 from looming patent cliffs 
• ~96% of oncology programs fail in the clinic 

With evolving science and technology, RefinedScience better understands how disease, patient, and cell diversity impacts diagnosis, response, resistance, and metastasis; however, clinical trials are often not informed with these insights. Additionally, a single person may generate terabytes of healthcare data, but defining, structuring, and analyzing this data to produce actionable insights continues to be a challenge.

A refined, smarter approach is needed.

Company Birth Story

RefinedScience started as part of CU Innovations, a technology transfer entity which provides a path to commercialization for the breakthrough work coming out of the University of Colorado (CU) Anschutz Medical Campus. What started as a small project seen as an aid for physicians making decisions in the clinic, has evolved into a new precision medicine platform and research organization making significant impacts for clinical trials and patient outcomes.

RefinedScience’s transformative insights were discovered by its world-class multi-disciplinary team of academic and industry experts. Their skilled research team is led by Chief Innovation Officer Clay Smith, M.D., Professor in the Division of Hematology at the University of Colorado (CU and Medical Director of CU Innovations. Clay served as the Director of the Blood Disorders and Cell Therapies Center at UCHealth and CU for over a decade.

Solution

HIGHLY CURATED PATIENT DATA

RefinedScience’s high-fidelity, curated, deep, fit-for-purpose data provides a comprehensive view of disease heterogeneity and precision patient targeting, and serves as the engine for innovation and differentiation. 

• CLINICAL DATA: RefinedScience has curated clinical data from diverse, real-world sources, including a unique and dynamic live-stream feed from a large, regional hospital system. They also ingest, structure, and analyze data from pharma and industry partners, federated data, and clinical trials enabling them to accumulate hundreds of clinical data points per patient. 
• BIOLOGIC SINGLE CELL DATA: RefinedScience has constructed the most expansive single-cell omics dataset in Acute Myeloid Leukemia (AML), including genomics, transcriptomics, and proteomics with millions of data points per patient derived from a continuously replenished biobank of tissue samples. Partnerships with hospital systems and others enable RefinedScience to replicate these one-of-a-kind datasets across diseases, e.g., hematology, oncology, immunology, and neuroscience.

CUTTING EDGE TECHNOLOGY & DATA PROCESSING

RefinedScience has created a team of expert data scientists to apply cutting-edge science and technology to the analysis of deep data, including the use of artificial intelligence (AI), machine learning (ML), and predictive models of toxicity and outcomes. Their approach includes:  

• Identification, abstraction, curation, and harmonization of data 
• Interrogation of data to discover patterns, trends, and correlations 
• Generation of transformative insights, advances, and new tools. 

Customer Impact

RefinedScience’s transformative approach to precision drug development is proven and scalable. Their work in Acute Myeloid Leukemia (AML) includes: 

• AML patients have poor survival rates and can develop resistance to standard of care targeted therapies. RefinedScience leveraged its proprietary, world-class AML dataset to uncover important targets, such as CD70, for patients who develop resistance. 
• RefinedScience took these insights to argenx with a CD70 drug candidate, cusatuzumab, that suggested promising results in a Phase 1b study. argenx and RefinedScience agreed to spin off a new joint venture called OncoVerity. 
• Applying RefinedScience’s transformative insights, OncoVerity designed a smart Phase 2 trial enriching for patients with unmet medical need with the potential for responses, increasing the probability of success.

CEO Quote 

“We bring together as much data as we can using fully curated data suites for a specific disease. It’s complicated work, but the insights we’re able to generate allow us to identify drugs that may not have gone through to commercialization yet and find the specific biomarkers that will allow them to work for patients who need them.”

–Erik Johnson, CEO, RefinedScience

Learn More

Website: https://www.refinedscience.com